



CMO/CDMO Service



Inquiry Flow



High Potency Facilities

Global Leader in Immunosuppressant API

Everolimus

Mycophenolate Mofetil

Rapamycin

Tacrolimus

Always a Team Player

With 75% of our business from North America and Europe, CCSB has been developing and producing APIs and advanced intermediates with leading Brand and Generic drug companies for years. Established in 1964, CCSB has commercialized several APIs of Anticancer, Antihypertriglyceridemic and Immunosuppressant with complete DMFs. Our state-of-the-art resources combined with highly skilled contract manufacturing team, we are GMP compliant, responsive, attentive, flexible and trustworthy. CCSB is an outstanding choice of partner to offer all of its clients the highest value.



Since 1964 in Taiwan

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.

1 Tung-Hsing St., Shu-Lin Dist. 23850, New Taipei City, Taiwan
 TEL: +886-2-8684-3318 FAX: +886-2-8684-3202
 Email: ccsb@ccsb.com.tw <http://www.ccsb.com.tw>

PHARMAPORTS LLC

1 East Uwchlan Avenue, Suite 116, Exton, PA 19341, USA
 TEL: (610) 524-7888 Toll Free: 1-800-203-1340
 Email: ppl@pharmaports.com

Synthetic / Natural API
Biotech / Fermentation API
Peptide API



Official cGMP Inspections

Year	Authorities	Nation	Product
2021	FDA	US	GMP Systems
2019	ANSM	France	Methocarbamol
2018	FDA	US	GMP Systems
2017	PMDA	Japan	Rapamycin
2017	FDA	US	Ethyl Icosapentate
2015	Cofepris	Mexico	Caspofungin Acetate
2015	Koln	Germany	Pravastatin Sodium; Tacrolimus
2014	FDA	US	GMP Systems
2013	MFDS	Korea	Tacrolimus
2013	PMDA	Japan	Tacrolimus
2012	Koln	Germany	Pravastatin Sodium
2011	FDA	US	Dexb; MMF; Tacrolimus
2009	Koln	Germany	Pravastatin Sodium
2007	MFDS	Korea	Methocarbamol
2005	FDA	US	Pravastatin Sodium

Synthetic / Natural API

Product Name	DMF	Spec.	Category
Abaloparatide		In-House	Osteoporosis
Baricitinib	36030	In-House	Rheumatoid Arthritis
Brivaracetam		In-House	Epilepsy
Carfilzomib	31276	In-House	Anticancer
Difelikefalin Acetate		In-House	CKD-Associated Pruritus
Edoxaban Tosylate		In-House	Anticoagulant
Eltrombopag Olamine		In-House	Hematology
Eslicarbazepine Acetate		In-House	Epilepsy, Seizures
Etelcalcetide HCl		In-House	Secondary Hyperparathyroidism with CKD
Ethyl Icosapentate (EPA>98%)	26271	In-House	Antihypertriglyceridemic; Cardiovascular Risk Reduction
Favipiravir	35849	In-House	Influenza; COVID-19
Lanreotide Acetate		In-House	Acromegaly; Neuroendocrine Tumors
Ozanimod HCl		In-House	Relapsing Multiple Sclerosis; Ulcerative Colitis
Palbociclib		In-House	Breast Cancer
Plecanatide		In-House	Chronic Idiopathic Constipation
Ribociclib Succinate	36174	In-House	Breast Cancer
Sacubitril Sodium		In-House	Heart Failure
Setmelanotide Acetate		In-House	Genetic Obesity
Sugammadex Sodium		In-House	Reversal Neuromuscular Blockade
Tofacitinib Citrate	37532	In-House	Rheumatoid Arthritis; Psoriatic Arthritis
Trandolapril	17573	EP/USP	Cardiovascular
Trilaciclib 2HCl		In-House	Myeloprotection

Biotech / Fermentation API

Product Name	DMF	Spec.	Category
Caspofungin Acetate	27585	In-House	Antifungal
Everolimus	26819 27216	EP/USP	Anticancer; Immunosuppressant
Midostaurin	36640	In-House	Acute Myeloid Leukemia; Systemic Mastocytosis
Mycophenolate Mofetil	18494 33333	EP/USP	Immunosuppressant
Mycophenolate Mofetil HCl	24372	In-House	Immunosuppressant
Mycophenolate Sodium	35848	EP/USP	Immunosuppressant
Rapamycin (Sirolimus)	17399 31189	In-House	Immunosuppressant
Tacrolimus	18985	EP/USP/JP	Immunosuppressant

Intermediates

Rapamycin (Sirolimus)

Pneumocandin B0

Paragraph IV Challenges & Paragraph III

Difelikefalin Acetate

Eltrombopag Olamine

Ozanimod HCl

Eslicarbazepine Acetate

Setmelanotide Acetate

Ribociclib Succinate

Trilaciclib 2HCl

Tofacitinib Citrate

The new pipeline product with unexpired patents on the product list is for the customer's study and trial purpose only and not for the preparation of commercial launch, if there exists any similar patent. CCSB will not be responsible for any use of the product which may infringe any valid patent.